JP2020507577A - Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 - Google Patents

Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 Download PDF

Info

Publication number
JP2020507577A
JP2020507577A JP2019543270A JP2019543270A JP2020507577A JP 2020507577 A JP2020507577 A JP 2020507577A JP 2019543270 A JP2019543270 A JP 2019543270A JP 2019543270 A JP2019543270 A JP 2019543270A JP 2020507577 A JP2020507577 A JP 2020507577A
Authority
JP
Japan
Prior art keywords
seq
amino acid
protein
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019543270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507577A5 (enExample
Inventor
グレゴリー ピー． チャン，
グレゴリー ピー． チャン，
アン エフ． チュン，
アン エフ． チュン，
ウィリアム ヘイニー，
ウィリアム ヘイニー，
ブラッドリー エム． ランディ，
ブラッドリー エム． ランディ，
ビアンカ プリンツ，
ビアンカ プリンツ，
Original Assignee
ドラゴンフライ セラピューティクス， インコーポレイテッド
ドラゴンフライ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラゴンフライ セラピューティクス， インコーポレイテッド, ドラゴンフライ セラピューティクス， インコーポレイテッド filed Critical ドラゴンフライ セラピューティクス， インコーポレイテッド
Publication of JP2020507577A publication Critical patent/JP2020507577A/ja
Publication of JP2020507577A5 publication Critical patent/JP2020507577A5/ja
Priority to JP2022074378A priority Critical patent/JP2022105121A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019543270A 2017-02-10 2018-02-10 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 Withdrawn JP2020507577A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022074378A JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457785P 2017-02-10 2017-02-10
US62/457,785 2017-02-10
PCT/US2018/017718 WO2018148610A1 (en) 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022074378A Division JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020507577A true JP2020507577A (ja) 2020-03-12
JP2020507577A5 JP2020507577A5 (enExample) 2021-03-25

Family

ID=63107819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543270A Withdrawn JP2020507577A (ja) 2017-02-10 2018-02-10 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
JP2022074378A Withdrawn JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022074378A Withdrawn JP2022105121A (ja) 2017-02-10 2022-04-28 Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質

Country Status (13)

Country Link
US (1) US20200024353A1 (enExample)
EP (1) EP3579878A4 (enExample)
JP (2) JP2020507577A (enExample)
KR (1) KR20190120770A (enExample)
CN (1) CN110913902A (enExample)
AU (1) AU2018217834A1 (enExample)
BR (1) BR112019016553A2 (enExample)
CA (1) CA3053275A1 (enExample)
IL (1) IL268574A (enExample)
MX (1) MX2019009541A (enExample)
RU (1) RU2019128204A (enExample)
SG (1) SG11201907271PA (enExample)
WO (1) WO2018148610A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
WO2023011431A1 (zh) * 2021-08-03 2023-02-09 江苏先声药业有限公司 一种cd16抗体及其应用
CN117915950A (zh) * 2021-08-06 2024-04-19 甘李药业股份有限公司 一种多特异性抗体及其用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500108A (ja) * 2000-03-24 2004-01-08 マイクロメット　アーゲー Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
JP2004517842A (ja) * 2000-12-13 2004-06-17 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー オキシラン化合物を調製する方法
JP2009514537A (ja) * 2005-11-03 2009-04-09 ジェネンテック・インコーポレーテッド 治療的抗ｈｅｒ２抗体融合ポリペプチド
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
US20120093719A1 (en) * 2009-04-14 2012-04-19 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2013531468A (ja) * 2010-04-15 2013-08-08 ジェネンテック， インコーポレイテッド 抗ユビキチン抗体及び使用方法
JP2013535187A (ja) * 2010-07-09 2013-09-12 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2014519322A (ja) * 2011-05-16 2014-08-14 フェイビオン ファーマシューティカルズ， インコーポレイテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP2014531894A (ja) * 2011-08-05 2014-12-04 ジェネンテック， インコーポレイテッド 抗ポリユビキチン抗体および使用方法
WO2016077505A2 (en) * 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
WO2016111344A1 (ja) * 2015-01-08 2016-07-14 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
MX380352B (es) * 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US10156574B2 (en) * 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
SG10201913324PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3258967A4 (en) * 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX387517B (es) * 2015-04-06 2025-03-18 Subdomain Llc Polipeptidos que contienen dominios de union de novo y usos de los mismos.

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500108A (ja) * 2000-03-24 2004-01-08 マイクロメット　アーゲー Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
JP2004517842A (ja) * 2000-12-13 2004-06-17 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー オキシラン化合物を調製する方法
JP2009514537A (ja) * 2005-11-03 2009-04-09 ジェネンテック・インコーポレーテッド 治療的抗ｈｅｒ２抗体融合ポリペプチド
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
US20120093719A1 (en) * 2009-04-14 2012-04-19 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2013531468A (ja) * 2010-04-15 2013-08-08 ジェネンテック， インコーポレイテッド 抗ユビキチン抗体及び使用方法
JP2013535187A (ja) * 2010-07-09 2013-09-12 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2014519322A (ja) * 2011-05-16 2014-08-14 フェイビオン ファーマシューティカルズ， インコーポレイテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2014531894A (ja) * 2011-08-05 2014-12-04 ジェネンテック， インコーポレイテッド 抗ポリユビキチン抗体および使用方法
WO2016077505A2 (en) * 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
WO2016111344A1 (ja) * 2015-01-08 2016-07-14 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KA YIN KWONG ET AL.: "Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibod", J MOL BIOL., vol. 384, no. 5, JPN7021005277, 2008, pages 1143 - 1156, ISSN: 0005073194 *
RON D. JACHIMOWICZ ET AL.: "Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Pr", MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 6, JPN7021005276, 2011, pages 1036 - 1045, ISSN: 0004653973 *

Also Published As

Publication number Publication date
AU2018217834A1 (en) 2019-08-22
RU2019128204A3 (enExample) 2021-07-16
CA3053275A1 (en) 2018-08-16
MX2019009541A (es) 2019-12-16
WO2018148610A1 (en) 2018-08-16
JP2022105121A (ja) 2022-07-12
IL268574A (en) 2019-09-26
EP3579878A1 (en) 2019-12-18
KR20190120770A (ko) 2019-10-24
RU2019128204A (ru) 2021-03-10
EP3579878A4 (en) 2020-11-18
CN110913902A (zh) 2020-03-24
BR112019016553A2 (pt) 2020-03-31
US20200024353A1 (en) 2020-01-23
SG11201907271PA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
JP7187518B2 (ja) Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン－１８．２を標的にする多重特異性結合タンパク質
JP7431392B2 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
US20210261668A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
JP7685821B2 (ja) Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
JP7257323B2 (ja) Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
JP2024099539A (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質
JP2023052214A (ja) Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
US20240018266A1 (en) Proteins binding cd123, nkg2d and cd16
JP2023030174A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2020506971A (ja) ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
JP2024012297A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2022105121A (ja) Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
JP2020521448A (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質
JP2020510644A (ja) Ｇｄ２、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
AU2018309712A1 (en) Proteins binding NKG2D, CD16 and FLT3
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
RU2788531C2 (ru) Белок, связывающийся с nkg2d, cd16 и с опухолеспецифическим антигеном
RU2820603C2 (ru) Белки, связывающие cd33, nkg2d и cd16
RU2805254C2 (ru) Белки, связывающие всма, nkg2d и cd16
HK40062610A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230303

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230306

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230602

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230803